Treatment of Infantile Spasms in Cryptogenic Cases with Normal Development Prior to Onset

This protocol addresses infantile spasms in infants who had normal development before spasm onset and have no identifiable underlying etiology — the cryptogenic presentation. The distinction from symptomatic cases directly shapes treatment selection.

Clinical Scenario

Cryptogenic infantile spasms are characterised by the absence of a clear etiology and a history of normal development prior to the onset of spasms. Patients in this group do not have tuberous sclerosis or another identifiable structural or metabolic cause. This is differentiated from symptomatic infantile spasms, which are defined by either abnormal development or a clear underlying etiology.

This distinction matters clinically: patients without an identified etiology may respond better to hormonal therapy than those with a defined cause.

Treatment Approach

First-line management in this setting centres on hormonal therapy. This class of intervention is broadly accepted as the primary first-line approach for infantile spasms, particularly in the cryptogenic setting.

The complete regimen — including specific agents, dosing schedule, escalation strategy, and taper — is available in the full structured protocol.

Clinical Goals

The primary therapeutic targets are complete cessation of clinical spasms and resolution of hypsarrhythmia on video EEG. Response is typically assessed within 14 days of initiating therapy.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3978/j.issn.2224-4336.2015.09.01

For simplicity, this review will use the dichotomous definition.
Defines symptomatic infantile spasms as those patients with either abnormal development and/or a clear etiology for the infantile spasms and cryptogenic spasms as those occurring in the context of normal development without a clear etiology.
For example, patients with tuberous sclerosis are more likely to respond to treatment with vigabatrin, whereas patients without an identified etiology may respond better to hormonal therapy.
ACTH is probably the most universally accepted first-line treatment of infantile spasms, stemming from the class 1 randomized controlled trials performed from 1983–1999 that show its efficacy.
The goals of therapy should include a complete cessation of the clinical events and resolution of hypsarrhythmia or modified hypsarrhythmia on video EEG.
Response is typically seen within 14 days or sooner.

View source ↗